NEW YORK, Nov. 27, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Abeona Therapeutics Inc. ABEO, Great Lakes Dredge & Dock Corporation GLDD, Imprimis Pharmaceuticals, Inc. IMMY, Alliant Energy Corporation LNT, Cytokinetics, Incorporated CYTK, and Aurinia Pharmaceuticals Inc AUPH, including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
ABEO DOWNLOAD: http://Fundamental-Markets.com/register/?so=ABEO
GLDD DOWNLOAD: http://Fundamental-Markets.com/register/?so=GLDD
IMMY DOWNLOAD: http://Fundamental-Markets.com/register/?so=IMMY
LNT DOWNLOAD: http://Fundamental-Markets.com/register/?so=LNT
CYTK DOWNLOAD: http://Fundamental-Markets.com/register/?so=CYTK
AUPH DOWNLOAD: http://Fundamental-Markets.com/register/?so=AUPH
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Fundamental Markets, available for free download at the links above, examine Abeona Therapeutics Inc. ABEO, Great Lakes Dredge & Dock Corporation GLDD, Imprimis Pharmaceuticals, Inc. IMMY, Alliant Energy Corporation LNT, Cytokinetics, Incorporated CYTK, and Aurinia Pharmaceuticals Inc AUPH on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed November 23rd, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.
-----------------------------------------
ABEONA THERAPEUTICS INC. (ABEO) REPORT OVERVIEW
Abeona Therapeutics' Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, Abeona Therapeutics reported revenue of $1.71MM vs $0.22MM (up 680.37%) and analysts estimated basic earnings per share -$0.34 vs -$0.13. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Abeona Therapeutics reported revenue of $0.84MM vs $0.89MM (down 5.85%) and analysts estimated basic earnings per share -$0.66 vs -$0.64. Analysts expect earnings to be released on March 15th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was -$0.19. The estimated EPS forecast for the next fiscal year is -$1.10 and is expected to report on March 15th, 2019.
To read the full Abeona Therapeutics Inc. (ABEO) report, download it here: http://Fundamental-Markets.com/register/?so=ABEO
-----------------------------------------
GREAT LAKES DREDGE & DOCK CORPORATION (GLDD) REPORT OVERVIEW
Great Lakes Dredge & Dock's Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, Great Lakes Dredge & Dock reported revenue of $204.32MM vs $163.32MM (up 25.11%) and analysts estimated basic earnings per share $0.19 vs -$0.05. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Great Lakes Dredge & Dock reported revenue of $702.50MM vs $767.59MM (down 8.48%) and analysts estimated basic earnings per share -$0.51 vs -$0.13. Analysts expect earnings to be released on February 19th, 2019. The report will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was -$0.12. The estimated EPS forecast for the next fiscal year is $0.45 and is expected to report on February 19th, 2019.
To read the full Great Lakes Dredge & Dock Corporation (GLDD) report, download it here: http://Fundamental-Markets.com/register/?so=GLDD
-----------------------------------------
IMPRIMIS PHARMACEUTICALS, INC. (IMMY) REPORT OVERVIEW
Imprimis Pharmaceuticals' Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, Imprimis Pharmaceuticals reported revenue of $10.74MM vs $6.48MM (up 65.65%) and analysts estimated basic earnings per share -$0.12 vs -$0.28. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Imprimis Pharmaceuticals reported revenue of $26.77MM vs $19.94MM (up 34.26%) and analysts estimated basic earnings per share -$0.60 vs -$1.50. Analysts expect earnings to be released on March 14th, 2019. The report will be for the fiscal period ending December 31st, 2018.
To read the full Imprimis Pharmaceuticals, Inc. (IMMY) report, download it here: http://Fundamental-Markets.com/register/?so=IMMY
-----------------------------------------
ALLIANT ENERGY CORPORATION (LNT) REPORT OVERVIEW
Alliant Energy's Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, Alliant Energy reported revenue of $928.60MM vs $906.90MM (up 2.39%) and basic earnings per share $0.87 vs $0.73 (up 19.18%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Alliant Energy reported revenue of $3,382.20MM vs $3,320.00MM (up 1.87%) and analysts estimated basic earnings per share $1.99 vs $1.64 (up 21.34%). Analysts expect earnings to be released on February 28th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $0.33. The estimated EPS forecast for the next fiscal year is $2.24 and is expected to report on February 28th, 2019.
To read the full Alliant Energy Corporation (LNT) report, download it here: http://Fundamental-Markets.com/register/?so=LNT
-----------------------------------------
CYTOKINETICS, INCORPORATED (CYTK) REPORT OVERVIEW
Cytokinetics' Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, Cytokinetics reported revenue of $10.64MM vs $6.18MM (up 72.18%) and analysts estimated basic earnings per share -$0.40 vs -$0.60. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Cytokinetics reported revenue of $13.37MM vs $106.41MM (down 87.44%) and analysts estimated basic earnings per share -$2.59 vs $0.41. Analysts expect earnings to be released on February 21st, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was -$0.75. The estimated EPS forecast for the next fiscal year is -$1.72 and is expected to report on February 21st, 2019.
To read the full Cytokinetics, Incorporated (CYTK) report, download it here: http://Fundamental-Markets.com/register/?so=CYTK
-----------------------------------------
AURINIA PHARMACEUTICALS INC (AUPH) REPORT OVERVIEW
Aurinia Pharmaceuticals' Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, Aurinia Pharmaceuticals reported revenue of $0.38MM vs $0.03MM (up 1,193.10%) and analysts estimated basic earnings per share -$0.21 vs -$0.16. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Aurinia Pharmaceuticals reported revenue of $0.42MM vs $0.17MM (up 142.77%) and analysts estimated basic earnings per share -$0.92 vs -$0.66. Analysts expect earnings to be released on March 21st, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was -$0.04. The estimated EPS forecast for the next fiscal year is -$0.72 and is expected to report on March 21st, 2019.
To read the full Aurinia Pharmaceuticals Inc (AUPH) report, download it here: http://Fundamental-Markets.com/register/?so=AUPH
-----------------------------------------
ABOUT FUNDAMENTAL MARKETS
Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.
REGISTERED MEMBER STATUS
Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.
LEGAL NOTICES
Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.
Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: media@Fundamental-Markets.com
© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
